Photoacoustic Tomography: Ultrasonically Breaking Through the Optical Diffusion Limit

Article

Photoacoustic tomography (PAT), a new imaging technique that relies on light and sound, provides in vivo multiscale nonionizing functional and molecular imaging without the radiation emitted by x-rays and CT scans, explained Lihong V. Wang, PhD, who led the team of developers at Washington University in St. Louis.

A wealth of data presented in posters, symposia, panel discussions, and plenary sessions at the 2012 meeting of the American Association for Cancer Research truly reflected this year’s theme, “Accelerating Science: Concept to Clinic.” The following is the first of a series of summaries of some of these presentations.

Photoacoustic tomography (PAT), a new imaging technique that relies on light and sound, provides in vivo multiscale nonionizing functional and molecular imaging without the radiation emitted by x-rays and CT scans, explained Lihong V. Wang, PhD, who led the team of developers at Washington University in St. Louis.

Lihong V. Wang, PhD

“PAT is the only modality capable of imaging across the length scales of organelles, cells, tissues, and organs with consistent contrast,” said Dr. Wang. The technique “has the potential to empower multiscale systems biology and accelerate translation from microscopic laboratory discoveries to macroscopic clinical practice.”

Dr. Wang said PAT may also hold the key to the earliest detection of cancer by in vivo label-free quantification of hypermetabolism, which he called “the quintessential hallmark of cancer.”

Dr. Wang is working with physicians at Washington University to evaluate PAT for use in identifying the sentinel lymph nodes for breast cancer staging (which may eliminate the need for surgical lymph node biopsies); monitoring early response to chemotherapy; imaging melanomas; and imaging the gastrointestinal tract.

“This technology is potentially a game changer, both in how we monitor cancer and in how soon we know it is there,” said Dr. Wang.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content